Pharmacotherapy. 2026 Mar;46(3):e70117. doi: 10.1002/phar.70117.
ABSTRACT
BACKGROUND: Drug-resistant epilepsy (DRE) is increasingly linked to neuroinflammatory mechanisms driven by gut dysbiosis. These mechanisms compromise blood-brain barrier integrity, enhance seizure susceptibility, and modulate immune pathways. These insights underscore the therapeutic potential of microbiota-targeted interventions in epilepsy.
AIM: The study aimed at assessing the effectiveness of probiotics as an adjunctive therapy to enhance drug sensitivity and clinical outcomes in children with DRE.
METHODS: This randomized, double-blind, placebo-controlled trial enrolled 60 pediatric patients with DRE who were assigned to either the control group (n = 30), which received a standard antiepileptic regimen (valproic acid, oxcarbazepine, and levetiracetam at the maximum tolerated doses) plus a daily placebo capsule, or the probiotic group (n = 30), which received the same antiepileptic regimen plus a daily probiotic (Lactobacillus acidophilus) supplement. The study duration was 6 months. Assessments of clinical and biochemical outcomes were conducted at baseline and 6 months after intervention. Primary end points included seizure frequency and change in quality of life as measured by the quality of life in childhood epilepsy (QOLCE-55) questionnaire. Secondary end points included the change in the serum levels of high-mobility group box 1 protein (HMGB1), interleukin-1β (IL-1β), homocysteine (Hcy), and NLR family pyrin domain-containing 3 (NLRP3).
RESULTS: After 6 months and relative to the control group, the probiotic (Lactobacillus acidophilus) group experienced a significant decline in seizure frequency (p = 0.04) and a significant improvement in the QOLCE-55 total score (p < 0.0001). Additionally, the probiotic group exhibited significant decreases in the serum levels of HMGB1 (p = 0.0005), NLRP3 (p = 0.002), Hcy (p = 0.001), and IL-1β (p = 0.05) compared with the control group.
CONCLUSION: Lactobacillus acidophilus supplementation appears to enhance the effectiveness of conventional antiepileptic drugs, reduce systemic inflammation, improve quality of life, and reduce seizure frequency in children with DRE. However, further validation is necessary.
GOV REGISTRATION NUMBER: NCT05539287.
PMID:41693686 | DOI:10.1002/phar.70117
